Last week, the FDA announced that it is investigating complaints about a generic version of GlaxoSmithKline's
The XL (extended release) version of the antidepressant developed in collaboration with Biovail
The FDA action probably won't be much help for the sales of Wellbutrin XL, which slipped from $364 million in the fourth quarter of last year to just $231 million in the second quarter after generics were introduced in December. Watson Pharmaceuticals
Perhaps the biggest winners of the investigation are drugmakers such as Alkermes
Extended Foolishness about extended-release drugs:
Flamel is a Motley Fool Hidden Gems newsletter pick. If small caps aren't your thing, why not pick up a 30-day free trial of our Income Investor newsletter, where you'll find Glaxo among the recommendations.